---
# === IDENTITY ===
id: business/sales-ops/pipeline-health-diagnostic/2026
canonical_question: "How healthy is a sales pipeline — stage distribution, aging, conversion rates, source mix with red flags?"
aliases:
  - "pipeline health diagnostic"
  - "sales pipeline assessment"
  - "pipeline health score"
  - "pipeline quality analysis"
  - "deal flow health check"
  - "pipeline aging and conversion analysis"
entity_type: assessment
domain: business > sales-ops > Pipeline Health Diagnostic
region: global
jurisdiction: global
temporal_scope: 2025-2026

# === VERIFICATION ===
last_verified: 2026-03-09
confidence: 0.85
version: 1.0
first_published: 2026-03-09

# === TEMPORAL VALIDITY ===
temporal_validity:
  status: evolving
  last_breaking_change: "2025 saw pipeline coverage requirements increase from 3x to 4x+ as win rates declined, redefining what 'healthy' coverage looks like"
  next_review: 2026-09-05
  change_sensitivity: medium

# === CONSTRAINTS ===
constraints:
  - "Requires at least 6 months of pipeline data for meaningful analysis; 12 months preferred for trend detection"
  - "CRM data quality directly limits diagnostic accuracy — garbage in, garbage out; if CRM data is unreliable, assess CRM utilization first"
  - "Pipeline health metrics are relative to your selling motion — an enterprise pipeline that looks 'thin' may be healthy if deal sizes are large enough"
  - "Assessment is point-in-time; pipeline health fluctuates seasonally and with market conditions — quarterly cadence recommended"
  - "This diagnostic identifies pipeline problems, not root causes — use dimension-specific cards for root cause analysis"

# === SKIP CONDITIONS ===
skip_this_unit_if:
  - condition: "User needs overall sales process maturity evaluation, not pipeline-specific"
    use_instead: "business/sales-ops/sales-process-maturity-assessment/2026"
  - condition: "User needs benchmark data for specific metrics like win rates or cycle times"
    use_instead: "business/sales-ops/sales-metrics-benchmarks/2026"
  - condition: "User needs to evaluate sales technology, not pipeline health"
    use_instead: "business/sales-ops/sales-tech-stack-assessment/2026"

# === AGENT HINTS ===
inputs_needed:
  - key: company_stage
    question: "What stage is the company?"
    type: choice
    options: ["Seed/Series A (<$2M ARR)", "Series B ($2M-$15M ARR)", "Growth ($15M-$100M ARR)", "Scale/Public ($100M+ ARR)"]
  - key: company_size
    question: "How many quota-carrying reps?"
    type: choice
    options: ["3-10 reps", "11-50 reps", "51-200 reps", "200+ reps"]
  - key: assessment_depth
    question: "What depth of diagnostic is needed?"
    type: choice
    options: ["quick health check (15 min)", "standard diagnostic (1 hour)", "deep pipeline audit (half day)"]
  - key: data_available
    question: "What pipeline data is accessible?"
    type: multi_select
    options: ["CRM pipeline report", "Stage conversion data", "Deal aging report", "Source/channel attribution", "Historical pipeline snapshots"]

# === DISTRIBUTION ===
canonical_source: "https://knowledgelib.io/business/sales-ops/pipeline-health-diagnostic/2026"
suggested_citation: "Source: knowledgelib.io — AI Knowledge Library (verified 2026-03-09)"

# === RELATED UNITS ===
related_kos:
  leads_to:
    - id: "business/sales-ops/sales-process-maturity-assessment/2026"
      label: "Broader process maturity assessment for systemic issues"
    - id: "business/sales-ops/sales-team-structure-benchmarks/2026"
      label: "Team structure adjustments when pipeline issues trace to staffing"
  related_to:
    - id: "business/sales-ops/sales-metrics-benchmarks/2026"
      label: "Benchmark data this diagnostic scores against"
    - id: "business/sales-ops/sales-tech-stack-assessment/2026"
      label: "Technology assessment when pipeline issues trace to tool gaps"
  depends_on: []
  often_confused_with: []
  alternative_to: []

# === SOURCES ===
sources:
  - id: src1
    title: "2025 GTM Benchmarks — Ebsta x Pavilion"
    author: Ebsta and Pavilion
    url: https://benchmarks.ebsta.com/2025-gtm-benchmarks
    type: primary_research
    published: 2025-03-01
    reliability: authoritative
  - id: src2
    title: "Pipeline Health: Definition, Examples & Use Cases"
    author: Saber
    url: https://www.saber.app/glossary/pipeline-health
    type: industry_report
    published: 2025-06-01
    reliability: high
  - id: src3
    title: "Sales Pipeline Analysis: Complete Guide to Pipeline Health & Optimization"
    author: CaptivateIQ
    url: https://www.captivateiq.com/blog/sales-pipeline-analysis
    type: industry_report
    published: 2025-04-01
    reliability: high
  - id: src4
    title: "Pipeline Predictability in 2026"
    author: RevSure
    url: https://www.revsure.ai/blog/pipeline-predictability-in-2026-the-new-discipline-of-revenue-confidence
    type: industry_report
    published: 2025-11-01
    reliability: high
  - id: src5
    title: "Pipeline Coverage Analysis: Measuring Pipeline Health Against Quota"
    author: Rework
    url: https://resources.rework.com/libraries/pipeline-management/pipeline-coverage-analysis
    type: industry_report
    published: 2025-08-01
    reliability: high
  - id: src6
    title: "Pipeline Generation Benchmarks by Industry: 2026 Guide"
    author: SaaS Hero
    url: https://www.saashero.net/content/pipeline-generation-industry-benchmarks/
    type: industry_report
    published: 2025-12-01
    reliability: high
---

# Pipeline Health Diagnostic

## Purpose

This diagnostic evaluates the health of a B2B sales pipeline across five critical dimensions: coverage adequacy, stage distribution, deal aging, conversion rates, and source diversity. The output is a composite health score with specific red flags and action triggers for each dimension. Unlike a process maturity assessment, this diagnostic is focused specifically on the pipeline itself — the deals, their quality, their progression, and their likelihood of converting to revenue. Use this when revenue is at risk, pipeline reviews feel unproductive, or forecasts are consistently unreliable. [src1]

## Constraints
<!-- Agents: read before running this diagnostic with a user. -->

- Requires at least 6 months of CRM pipeline data; 12 months preferred for seasonal pattern detection
- CRM data quality is the prerequisite — if field completion is below 70% or stage definitions are inconsistent, assess CRM first
- Pipeline health is relative to selling motion — enterprise pipelines are naturally thinner with larger deals; SMB pipelines are higher-volume with smaller deals
- This is a point-in-time diagnostic — pipeline health fluctuates quarterly; run on a regular cadence, not just when problems are suspected
- Identifies pipeline problems but not root causes — use complementary cards for diagnosis

## Assessment Dimensions

### Dimension 1: Coverage Adequacy

**What this measures**: Whether the pipeline contains enough potential revenue to reliably hit quota targets, weighted by realistic conversion probability.

| Score | Level | Description | Evidence |
|-------|-------|-------------|----------|
| 1 | Critical | Unweighted coverage below 2x quota; virtually no chance of hitting target | Pipeline-to-quota ratio under 2:1; less than 20% of pipeline in commit stages; weekly pipeline additions insufficient to close gap |
| 2 | At Risk | Coverage 2x-3x but heavily concentrated in early stages with low conversion probability | Majority of pipeline in discovery/qualification stages; less than 30% in proposal/negotiation; win-weighted coverage below 1.5x |
| 3 | Adequate | Coverage 3x-4x with reasonable stage distribution; on track for 80-100% attainment | Healthy distribution across stages; win-weighted coverage 1.5x-2x; consistent weekly pipeline additions |
| 4 | Strong | Coverage 4x-5x with strong late-stage concentration; high confidence in forecast | Significant pipeline in proposal/negotiation stages; win-weighted coverage 2x-3x; multiple commit-level deals |
| 5 | Excellent | Coverage exceeds 5x with balanced distribution; forecast accuracy above 90% | Surplus pipeline at all stages; win-weighted coverage above 3x; pipeline generation exceeds consumption rate |

**Red flags**: Coverage below 2.5x at start of quarter; more than 50% of pipeline created in current quarter (not enough aging time to close); pipeline declining week-over-week. [src5]
**Quick diagnostic question**: "What is your current pipeline-to-quota ratio, and what percentage of that pipeline is in proposal stage or later?"

### Dimension 2: Stage Distribution

**What this measures**: Whether deals are distributed across pipeline stages in a pattern consistent with healthy progression, or concentrated in ways that signal problems.

| Score | Level | Description | Evidence |
|-------|-------|-------------|----------|
| 1 | Critical | 80%+ of pipeline in one stage (usually early); obvious bottleneck or stage-skipping | Pipeline clumped at discovery; virtually nothing in negotiation; or deals jump from early to Closed Won |
| 2 | Unhealthy | Significant imbalance — too top-heavy (leads not converting) or too bottom-heavy (pipeline generation stalled) | More than 60% in stages 1-2; less than 10% in stages 4-5; or reverse — all late-stage, no new pipeline |
| 3 | Balanced | Gradually narrowing funnel with more deals at top and fewer but higher-probability deals at bottom | 35-45% in early stages, 25-35% in mid-stages, 20-30% in late stages (by count); consistent with historical patterns |
| 4 | Optimized | Distribution matches historical conversion patterns; each stage has appropriate volume to feed downstream | Stage volumes calibrated to historical conversion rates; pipeline refresh rate matches consumption rate |
| 5 | Predictive | AI-optimized stage distribution with dynamic rebalancing; predictive models flag distribution anomalies | Real-time distribution monitoring; automated alerts for distribution drift; stage volumes auto-adjusted for seasonal patterns |

**Red flags**: More than 40% of pipeline value in stage 1 (top-heavy); less than 15% in stage 4+ (no close-ready deals); stage 3 has more deals than stage 2 (skip-staging). [src3]
**Quick diagnostic question**: "What percentage of your pipeline value is in the last two stages before close?"

### Dimension 3: Deal Aging & Velocity

**What this measures**: Whether deals are progressing through the pipeline at appropriate speeds, or stalling and aging past their likely close date.

| Score | Level | Description | Evidence |
|-------|-------|-------------|----------|
| 1 | Critical | More than 30% of pipeline exceeds 2x the average cycle length; stale deals inflating coverage | Large number of deals at 180+ days in a 90-day sales cycle; no systematic deal hygiene; stale deals counted in forecast |
| 2 | Unhealthy | 15-30% of pipeline is aged beyond 1.5x average cycle; some deals recycled through stages without genuine progress | Deals sitting in same stage for 30+ days; manual stage-backs to avoid aging alerts; pipeline "churning" without real progress |
| 3 | Healthy | Less than 15% of pipeline exceeds average cycle length; most deals progress through stages at expected velocity | Median deal age aligns with historical norms; stage-by-stage velocity consistent; stale deal cleanup happens monthly |
| 4 | Efficient | Pipeline velocity is improving quarter-over-quarter; aging distribution tight around median | 90th percentile age within 1.5x of median; velocity improvements measurable; deals that stall are identified and addressed within 2 weeks |
| 5 | Optimized | AI monitors deal velocity in real-time; aging anomalies flagged automatically; dead deals removed proactively | Zero stale deals in forecast; AI identifies at-risk deals based on activity patterns before they visibly stall; cycle time improvements tracked per segment |

**Red flags**: Deals exceeding 2x average cycle length still counted in forecast; stage regression used to reset aging clocks; same opportunity appears in 3+ consecutive quarterly forecasts; velocity slowing quarter-over-quarter. [src2]
**Quick diagnostic question**: "How many deals in your current pipeline are older than your average sales cycle, and are they still in the forecast?"

### Dimension 4: Conversion Rate Consistency

**What this measures**: Whether stage-to-stage conversion rates are stable and predictable, or erratic in ways that signal qualification or process issues.

| Score | Level | Description | Evidence |
|-------|-------|-------------|----------|
| 1 | Critical | No conversion data tracked; or conversion rates vary more than 50% quarter-to-quarter | No stage conversion reporting; win rates swing wildly; no ability to predict pipeline-to-revenue yield |
| 2 | Inconsistent | Conversion rates tracked but volatile; 25-50% variance quarter-to-quarter; large gaps between rep-level rates | Some quarters 20% win rate, others 35%; top rep conversion 3x bottom rep; no investigation into variance drivers |
| 3 | Stable | Conversion rates consistent within 15% quarter-over-quarter; segmented by source and deal size | Win rate variance under 15%; conversion tracked by stage, source, and rep; outliers investigated |
| 4 | Predictive | Conversion rates reliable enough for accurate forecasting; source-weighted conversion used for pipeline valuation | Source-adjusted win rates used in forecast models; conversion predictions accurate within 10%; regression models identify conversion drivers |
| 5 | Optimized | AI-driven conversion prediction at deal level; real-time conversion rate monitoring with anomaly detection | Deal-level win probability based on 10+ signals; conversion models continuously retrained; forecast accuracy above 90% |

**Red flags**: Win rates below 15% (qualification is broken); conversion rates vary more than 2x across reps (process adherence issue); stage 1 to stage 2 conversion below 50% (too many unqualified deals entering pipeline). [src1]
**Quick diagnostic question**: "What is your win rate, and has it changed more than 15% in either direction in the last two quarters?"

### Dimension 5: Source Diversity & Quality

**What this measures**: Whether pipeline is generated from multiple channels with appropriate quality variation, or dangerously concentrated in one source.

| Score | Level | Description | Evidence |
|-------|-------|-------------|----------|
| 1 | Critical | 80%+ of pipeline from a single source; complete dependence on one channel | All pipeline from founder/CEO relationships; or 100% inbound with no outbound; or 100% outbound with no marketing |
| 2 | Concentrated | 60-80% from one source; secondary sources exist but are immaterial | One channel dominates; secondary sources produce less than 20% each; no channel development plan |
| 3 | Diversified | No single source exceeds 50% of pipeline; 3+ meaningful channels contributing | Inbound 30-40%, outbound 25-35%, partners/referrals 15-25%, other 10-15%; each source has measurable contribution |
| 4 | Optimized | Multi-channel pipeline with source-specific conversion tracking; dynamic budget allocation based on channel efficiency | Channel ROI measured and compared; budget shifts based on conversion performance; source-specific deal velocity tracked |
| 5 | Orchestrated | Integrated multi-channel pipeline generation with AI-driven channel optimization; account-based orchestration across sources | ABM motions coordinate across channels per account; AI optimizes channel mix per segment; real-time source performance monitoring |

**Red flags**: Single-source dependence (if that source fails, pipeline goes to zero); marketing-sourced pipeline below 30% at growth stage; outbound pipeline below 20% at scale stage; partner channel producing volume but at much lower win rates. [src6]
**Quick diagnostic question**: "What percentage of your pipeline comes from your top source, and what happens to your number if that source declines 30%?"

## Scoring & Interpretation

### Overall Score Calculation

All dimensions are weighted equally for a general health check. For companies specifically concerned about forecast accuracy, weight Coverage and Conversion 1.5x.

```
Overall Score = (Coverage + Stage Distribution + Deal Aging + Conversion Rates + Source Diversity) / 5
```

### Score Interpretation

| Overall Score | Health Level | Interpretation | Recommended Next Step |
|---------------|-------------|----------------|----------------------|
| 1.0 - 1.9 | Critical | Pipeline will not support revenue targets; immediate intervention required | Emergency pipeline generation sprint; clean stale deals; establish basic stage definitions |
| 2.0 - 2.9 | At Risk | Pipeline has significant weaknesses; forecast reliability is low | Identify the weakest dimension; address that one issue before optimizing others |
| 3.0 - 3.9 | Healthy | Pipeline fundamentals are solid; targeted optimization will improve predictability | Fine-tune stage conversion rates; implement source-weighted coverage model |
| 4.0 - 4.5 | Strong | High-performing pipeline; focus on predictability and efficiency gains | Advanced analytics; AI-powered deal scoring; channel ROI optimization |
| 4.6 - 5.0 | Best-in-class | Pipeline is a predictable revenue machine; focus on maintaining and innovating | Maintain cadence; experiment with new channels; share best practices |

### Dimension-Level Action Routing

| Weak Dimension (Score < 3) | Fetch This Card |
|----------------------------|-----------------|
| Coverage Adequacy | [Sales Metrics Benchmarks](/business/sales-ops/sales-metrics-benchmarks/2026) — review pipeline coverage and generation benchmarks |
| Stage Distribution | [Sales Process Maturity Assessment](/business/sales-ops/sales-process-maturity-assessment/2026) — stage issues reflect process issues |
| Deal Aging & Velocity | [Sales Metrics Benchmarks](/business/sales-ops/sales-metrics-benchmarks/2026) — review sales cycle benchmarks |
| Conversion Rates | [Sales Process Maturity Assessment](/business/sales-ops/sales-process-maturity-assessment/2026) — conversion issues trace to methodology |
| Source Diversity | [Sales Team Structure Benchmarks](/business/sales-ops/sales-team-structure-benchmarks/2026) — SDR/AE allocation affects source mix |

## Benchmarks by Segment

| Segment | Expected Average Score | "Good" Threshold | "Alarm" Threshold |
|---------|----------------------|-------------------|-------------------|
| Seed/Series A (<$2M ARR) | 2.0 | 2.5 | 1.5 |
| Series B ($2M-$15M ARR) | 2.8 | 3.3 | 2.0 |
| Growth ($15M-$100M ARR) | 3.5 | 4.0 | 2.5 |
| Scale/Public ($100M+ ARR) | 4.0 | 4.5 | 3.0 |

[src1]

## Common Pitfalls in Assessment

- **Coverage inflation from stale deals**: The most common pipeline health error. Companies report 4x coverage, but when stale deals (>2x cycle length) are removed, real coverage is 2.5x. Always clean before measuring. [src2]
- **Ignoring source quality differences**: A pipeline that is 4x from inbound (30% win rate) is worth more than 4x from cold outbound (15% win rate). Weight coverage by source-specific conversion rates for accurate assessment.
- **Snapshot instead of trend**: A healthy pipeline today can mask a dangerous trajectory. If pipeline generation is declining 10% month-over-month while quota is flat, the company is 2-3 quarters from a crisis. Always assess the trend, not just the snapshot.
- **Confusing activity with quality**: High pipeline creation volume does not equal health if win rates are simultaneously declining. "Pipeline production is up 20%" combined with "win rates are down 30%" means the quality has degraded — more is not better.

## When This Matters

Fetch when a user asks to evaluate pipeline health, diagnose why the team is missing quota despite sufficient activity, prepare for a quarterly business review, investigate forecast accuracy problems, or assess whether pipeline generation investments are producing results.

## Related Units

- [Sales Metrics Benchmarks](/business/sales-ops/sales-metrics-benchmarks/2026)
- [Sales Process Maturity Assessment](/business/sales-ops/sales-process-maturity-assessment/2026)
- [Sales Team Structure Benchmarks](/business/sales-ops/sales-team-structure-benchmarks/2026)
- [Sales Tech Stack Assessment](/business/sales-ops/sales-tech-stack-assessment/2026)